糖尿病視網膜病變：按類型（非增殖性 DR、增殖性 DR）、管理（抗 VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-2023-2030 年世界市場預測

糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、管理（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界全球市場預計將顯著增長2023年將達到3.7638億美元，複合年增長率為17.62%，2030年將達到11.772億美元。

FPNV定位矩陣

全球糖尿病視網膜病變的FPNV 定位矩陣：按類型（非增殖性DR、增殖性DR）、管理（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-世界對評估市場至關重要。 通過檢查業務戰略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的具體需求做出明智的決策。 這種高級分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場份額分析

市場份額分析可以深入了解供應商在特定市場區域的當前狀態。 比較供應商對整體收入、客戶群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場份額時的表現以及面臨的情況。 該分析還揭示了特定行業的競爭程度、積累和分散的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要公司所服務的市場的全面信息。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細信息，並分析其在成熟市場領域的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新開發和投資的詳細信息。

4. 市場趨勢：全面了解 COVID-19、俄羅斯-烏克蘭衝突和高通脹的累積影響。

5.競爭評估和信息：對主要公司的市場份額、戰略、產品、認證、監管狀況、專利狀況、製造能力進行綜合評估。

6. 產品開發和創新：提供對未來技術、研發活動和突破性產品開發的見解。

此報告回答了以下問題：

1.糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-全球市場規模和預測？

2.預測期內，全球糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、管理（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-什麼COVID-19 對塑造全球市場有何障礙和影響？

3.糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-全球市場有哪些產品/在預測期內我們應該投資哪些細分市場/應用/領域？

4.糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-在全球市場上您的競爭力是什麼戰略？

5.糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界全球市場有哪些技術趨勢和監管框架？

6.糖尿病視網膜病變：按類型（非增殖性 DR、增殖性 DR）、治療（抗 VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-全球市場是什麼主要供應商的份額？

7.糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、管理（抗VEGF治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-走向全球市場什麼形式和您認為適合進入的戰略舉措嗎？

目錄

第一章前言

第二章研究方法

第 3 章執行摘要

第四章市場概述

第 5 章市場洞察

• 市場動態
  • 驅動程序
    • 世界範圍內糖尿病的患病率正在上升
    • 提高對糖尿病管理和護理的認識
    • 政府促進糖尿病管理的舉措
  • 抑制因素
    • 缺乏熟練的眼科醫生
  • 機會
    • 晚期糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界治療方法和持續引入藥物
    • 治療糖尿病黃斑水腫的聯合療法的出現
  • 作業
    • 糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界藥物審批流程所需的時間
• 市場趨勢
• 新冠肺炎 (COVID-19) 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通脹的累積影響
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 監管框架
• 客戶定制

第6 章糖尿病視網膜病變：類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-世界市場：另一種類型

• 非增殖性 DR
• 增殖性 DR

第7 章糖尿病視網膜病變：按類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界市場經理另一個

• 抗 VEGF 治療
• 眼內類固醇注射
• 激光手術
• 玻璃體手術

第8 章美洲糖尿病視網膜病變：類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通脹-世界市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章亞太地區糖尿病視網膜病變：類型（非增殖性DR、增殖性DR）、治療（抗VEGF治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高通貨膨脹-世界市場

• 澳大利亞
• 中國
• 印度
• 印度尼西亞
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10 章歐洲、中東和非洲的糖尿病視網膜病變：類型（非增殖性DR、增殖性DR）、治療（抗VEGF 治療、眼內類固醇注射、激光手術）-俄羅斯-烏克蘭衝突和高風險通貨膨脹- 世界市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 意大利
• 荷蘭
• 尼日利亞
• 挪威
• 波蘭
• 卡塔爾
• 俄羅斯
• 沙特阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合酋長國
• 英國

第11章競爭態勢

• FPNV定位矩陣
• 市場份額分析：按主要公司劃分
• 競爭情景分析：主要公司

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和價格

The Global Diabetic Retinopathy Market is forecasted to grow significantly, with a projected USD 376.38 million in 2023 at a CAGR of 17.62% and expected to reach a staggering USD 1,177.20 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Diabetic Retinopathy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Diabetic Retinopathy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Non-proliferative DR and Proliferative DR. The Proliferative DR is projected to witness significant market share during forecast period.

Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy. The Laser Surgery is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Diabetic Retinopathy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetic Retinopathy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetic Retinopathy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetic Retinopathy Market?

4. What is the competitive strategic window for opportunities in the Global Diabetic Retinopathy Market?

5. What are the technology trends and regulatory frameworks in the Global Diabetic Retinopathy Market?

6. What is the market share of the leading vendors in the Global Diabetic Retinopathy Market?

7. What modes and strategic moves are considered suitable for entering the Global Diabetic Retinopathy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Diabetic Retinopathy Market, by Type, 2022 vs 2030
• 4.3. Diabetic Retinopathy Market, by Management, 2022 vs 2030
• 4.4. Diabetic Retinopathy Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diabetes globally
    • 5.1.1.2. Increasing awareness associated with diabetic management and care
    • 5.1.1.3. Government initiatives to promote the diabetes management
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of skilled ophthalmologists
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
  • 5.1.4. Challenges
    • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Diabetic Retinopathy Market, by Type

• 6.1. Introduction
• 6.2. Non-proliferative DR
• 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

• 7.1. Introduction
• 7.2. Anti-VEGF Therapy
• 7.3. Intraocular Steroid Injection
• 7.4. Laser Surgery
• 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

1. Alimera Sciences, Inc.

2. Allergan PLC

3. Ampio Pharmaceuticals, Inc.

4. Bausch & Lomb Incorporated

5. Bayer AG

6. BCN PEPTIDES, S.A.U.

7. F. Hoffmann-La Roche AG

8. Kodiak Sciences Inc.

9. Kowa Company, Ltd.

10. Novartis AG

11. Opthea Limited

12. Oxurion NV

13. Pfizer Inc.

14. Regeneron Pharmaceuticals Inc.

15. Sirnaomics Inc.

LIST OF FIGURES

• FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
• FIGURE 2. DIABETIC RETINOPATHY MARKET SIZE, 2022 VS 2030
• FIGURE 3. DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2022 VS 2030 (%)
• FIGURE 6. DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. DIABETIC RETINOPATHY MARKET DYNAMICS
• FIGURE 8. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 8. DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. DIABETIC RETINOPATHY MARKET SIZE, BY INTRAOCULAR STEROID INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. DIABETIC RETINOPATHY MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. DIABETIC RETINOPATHY MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 15. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 17. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 19. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 21. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 29. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 31. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 33. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 35. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 37. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 39. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 41. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 43. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 45. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 47. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 49. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 51. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 56. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 58. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 60. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 62. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 64. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 66. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 68. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 70. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 72. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 74. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 76. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 78. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 80. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 82. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 86. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 88. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 90. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 92. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 94. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 96. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 98. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 99. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 100. DIABETIC RETINOPATHY MARKET LICENSE & PRICING